Clinical Trials Logo

Human Immunodeficiency Virus clinical trials

View clinical trials related to Human Immunodeficiency Virus.

Filter by:

NCT ID: NCT01814722 Terminated - Clinical trials for Human Immunodeficiency Virus

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

Start date: November 2012
Phase: N/A
Study type: Observational

This is a multi-center, longitudinal observational study of adult human immunodeficiency virus (HIV) participants at academic and community-based practices in the United States who are switching from first-line to second-line therapy. The study's primary hypothesis is that HIV participants switching to raltegravir-based regimens will have better Medical Outcomes Study-HIV (MOS-HIV) Health Survey scores than participants switched to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens.

NCT ID: NCT01692236 Terminated - Clinical trials for Human Immunodeficiency Virus

Brain Imaging for HIV-Associated Thinking and Mood Disorders

Start date: September 13, 2012
Phase:
Study type: Observational

Background: - Human immunodeficiency virus (HIV) infection appears to cause problems with blood vessel function. These problems may add to some thinking and mood disorders found in people with HIV infection. Researchers want to evaluate HIV infected patients to see if blood vessel function contributes to thinking and mood disorders, such as early dementia and depression. To do so, they will compare study results between people with and people without HIV infection. Objectives: - To compare the thickness of blood vessel walls between people with and without HIV infection. - To study the relationship between blood vessel thickness and thinking and mood disorders. Eligibility: - Individuals between 25 and 55 years of age who have HIV infection. - Healthy individuals between 25 and 55 years of age. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. - Participants will have imaging studies of the brain and major blood vessels in the head and neck. - Participants will also have neuropsychological testing. These tests will look at memory, learning and thinking ability, attention, and mood. - Participants will have the option of coming back for repeat blood tests every six months and repeat imaging studies and neuropsychological tests every year, over 1- 4 years period.

NCT ID: NCT01420523 Terminated - Clinical trials for Human Immunodeficiency Virus

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

ROCnRAL
Start date: December 2011
Phase: Phase 2
Study type: Interventional

Evaluation of antiretroviral therapy combining Raltegravir and Maraviroc in patients with virological success, presenting with clinical lipohypertrophy.

NCT ID: NCT00781287 Terminated - Clinical trials for Human Immunodeficiency Virus

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

UW PIC 330
Start date: February 2009
Phase: Phase 4
Study type: Interventional

This is an investigator-initiated, two-year, randomized, controlled, single-center, open-label, pilot study comparing 3-drug highly active antiretroviral therapy (HAART) to 3-drug HAART plus raltegravir for persons with acute and early HIV-1 infection. The study will test the hypothesis that use of the integrase inhibitor raltegravir (400 mg BID orally) to inhibit the integration step of the HIV-1 life cycle in conjunction with HAART in subjects with recently acquired HIV-1 infection will decrease the number of HIV-1 infected CD4+ T-cells to a greater extent than a 3-drug HAART regimen.

NCT ID: NCT00678587 Terminated - HIV Infection Clinical Trials

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

ELEVATE
Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive procedures. The clinical benefit of eltrombopag will be measured by the proportion of subjects who avoid platelet transfusions, before, during and up to 7 days after undergoing an invasive procedure. In addition, bleeding events will be monitored during this time. The number of transfusions, safety events and medical resource utilisation will be monitored during this time and for up to 30 days after undergoing an invasive procedure to help further evaluate clinical benefit.

NCT ID: NCT00300573 Terminated - HIV Infections Clinical Trials

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

DECLARE
Start date: April 2006
Phase: Phase 2
Study type: Interventional

The study will compare the safety and efficacy of an investigation nucleoside analog reverse transcriptase inhibitor (NRTI), dexelvucitabine (DFC), to an approved NRTI, lamivudine (3TC) in HIV treatment-experienced patients who are resistant to 3 classes of antiretroviral therapies (NRTIs, PIs and NNRTIs). Patients meeting eligibility requirements will have a new 'optimized' background regimen (OBR) selected for them by their investigator based on prior ARV treatment history and the results of HIV genotype and phenotype tests performed during the screening period. In addition to treatment with the new OBR, patients will be randomized to receive treatment with either DFC or 3TC in a blinded fashion. There is a 50 percent chance a patient will receive DFC or 3TC. Treatment in the study may continue for up to 96 weeks. Patients with an inadequate response to therapy after 16 weeks will have the option to change their OBR and the option to switch to receive the other study medication (i.e., DFC to 3TC or 3TC to DFC).